Difference between revisions of "Plasma cell leukemia"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m (Text replacement - "<span style="background:#eeee00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase II</span>" to "style="background-color:#EEEE00"|Phase II") |
||
| Line 25: | Line 25: | ||
|- | |- | ||
|[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013] | |[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013] | ||
| − | | | + | |style="background-color:#EEEE00"|Phase II |
| − | style="background | ||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
| Line 58: | Line 53: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/34/18/2125.full Royer et al. 2016] | |[http://jco.ascopubs.org/content/34/18/2125.full Royer et al. 2016] | ||
| − | | | + | |style="background-color:#EEEE00"|Phase II |
| − | style="background | ||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
| Line 100: | Line 90: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/34/18/2125.full Royer et al. 2016] | |[http://jco.ascopubs.org/content/34/18/2125.full Royer et al. 2016] | ||
| − | | | + | |style="background-color:#EEEE00"|Phase II |
| − | style="background | ||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
| Line 131: | Line 116: | ||
|- | |- | ||
|[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013] | |[http://www.nature.com/leu/journal/v28/n1/full/leu2013241a.html Musto et al. 2013] | ||
| − | | | + | |style="background-color:#EEEE00"|Phase II |
| − | style="background | ||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
Revision as of 05:57, 4 December 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site Are you looking for a regimen but can't find it here? It is possible that we've moved it to the obsolete regimens page. If you still can't find it, please let us know so we can add it!.
4 regimens on this page
4 variants on this page
|
Untreated
Ld
| back to top |
Ld: Lenalidomide, low dose dexamethasone
Regimen
| Study | Evidence |
| Musto et al. 2013 | Phase II |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
28-day cycle for 4 cycles
Responding patients eligible for transplant proceeded to SCT per center protocol. Responding patients ineligible for transplant received 4 more cycles of Ld, followed by lenalidomide maintenance.
References
- Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed
PAD/VCD
| back to top |
PAD: PS-341 (Bortezomib), Adriamycin liposomal (Doxorubicin liposomal), Dexamethasone
VCD: Velcade (Bortezomib), Cyclophosphamide, Dexamethasone
Regimen
| Study | Evidence |
| Royer et al. 2016 | Phase II |
PAD portion
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
- Doxorubicin liposomal (Doxil) 30 mg/m2 IV once on day 4
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 4, 8, 11
Two 21-day cycles (1 & 3), alternating with VCD
VCD portion
- Bortezomib (Velcade) 1.3 mg/m2 SC once per day on days 1, 4, 8, 11
- Cyclophosphamide (Cytoxan) 300 mg/m2 PO once per day on days 1 & 8
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 4, 8, 11
Two 21-day cycles (2 & 4), alternating with PAD
Responding patients proceeded to undergo high-dose melphalan & autologous stem cell transplant.
References
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains verified protocol PubMed
Consolidation after upfront therapy
Melphalan -> autologous stem cell transplant
| back to top |
Regimen
| Study | Evidence |
| Royer et al. 2016 | Phase II |
Treatment preceded by PAD alternating with VCD.
Chemotherapy
- Melphalan (Alkeran) 200 mg/m2 IV once
- Patients > 65 years or with CrCl < 30 mL/min received 140 mg/m2
References
- Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains protocol PubMed
Maintenance therapy
Lenalidomide (Revlimid)
| back to top |
Regimen
| Study | Evidence |
| Musto et al. 2013 | Phase II |
Treatment preceded by Ld x 8.
Chemotherapy
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles until progression
References
- Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014 Jan;28(1):222-5. Epub 2013 Aug 20. link to original article contains verified protocol PubMed